Randomized, open label, controlled clinical trial of eldcalcitol for falls prevention in postmenopausal osteoporotic patients with depression.

Randomized, open label, controlled clinical trial of eldcalcitol for falls prevention in postmenopausal osteoporotic patients with depression. - Efficacy of eldcalcitol for falls prevention in postmenopausal osteoporotic patients with depression.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011670

Enrollment

200

Registered

2013-09-10

Start date

2013-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Falls

Interventions

eldecalcitol, 0.75&amp

micro

g/day raloxifene, 60mg/day raloxifene, 60mg/day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal osteoporotic patients with depression Aged 50 and over

Exclusion criteria

Exclusion criteria: Patients who are diagnosed as contraindication of raloxifene treatments Patients who are diagnosed as contraindication of eldecalcitol treatments Patient who have a past history of treatment with vitamin D within 6 months Patient who have a past history of treatment for osteoporosis besides vitamin D in the past 12-months Unsuitable for trial as evaluated by the physician-in-charge Subject who refuse to participate in this study

Design outcomes

Primary

Measure	Time frame
Falls rate	—

Secondary

Measure	Time frame
falls related injury Hamilton raing scale for depression physical function bone mineral density mauscle volume markers of bone metabolism falls efficacy scale	—

Countries

Japan

Contacts

Public ContactTetsuya Enishi

Tokushima University Hospital Division of Rehabilitation, Tokushima University Hospital

enishi.tetsuya@tokushima-u.ac.jp088-633-9313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026